ORAMED PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Mar 6, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 6, 2024
ORMP$3.97-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of income (loss)
| Year ended December 31, | Year ended December 31, | |
|---|---|---|
| 2023 | 2022 | |
| REVENUES | $1,340 | $2,703 |
| RESEARCH AND DEVELOPMENT EXPENSES | (8,971) | (27,639) |
| SALES AND MARKETING | 287 | (1,851) |
| GENERAL AND ADMINISTRATIVE EXPENSES | (8,425) | (13,811) |
| OPERATING LOSS | (15,769) | (40,598) |
| INTEREST EXPENSES (note 11b) | (2,037) | - |
| FINANCIAL INCOME (EXPENSES), NET (note 11a) | 22,894 | 2,934 |
| INCOME (LOSS) BEFORE TAX EXPENSES | 5,088 | (37,664) |
| TAX EXPENSES | - | (100) |
| NET LOSS (INCOME) | $5,088 | $(37,764) |
| NET INCOME (LOSS) ATTRIBUTABLE TO: | ||
| COMPANY’S STOCKHOLDERS | 5,525 | (36,561) |
| NON-CONTROLLING INTERESTS | (437) | (1,203) |
| NET INCOME (LOSS) | $5,088 | $(37,764) |
| BASIC INCOME (LOSS) PER SHARE OF COMMON STOCK | $0.14 | $(0.94) |
| DILUTED INCOME (LOSS) PER SHARE OF COMMON STOCK | $0.14 | $(0.94) |
| WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING BASIC INCOME (LOSS) PER SHARE OF COMMON STOCK | 40,315,068 | 38,997,649 |
| WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING DILUTED INCOME (LOSS) PER SHARE OF COMMON STOCK | 40,566,901 | 38,997,649 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.